Adding testosterone to combination hormone therapy with estrogen and progesterone may counteract breast cell proliferation in postmenopausal women, according to the results of a 6-month, prospective, randomized, double-blind, placebo-controlled trial.
In the study, 99 post-menopausal women received continuous combined estradiol 2 mg/norethisterone acetate 1 mg and either a testosterone patch releasing 300 µg/24 hours or a placebo patch.
The women in the placebo group had more than a fivefold increase in total breast cell proliferation from a median value of 1.1% at baseline to a median of 6.2% after 6 months (P<0.001). No such increase occurred in the testosterone group (1.6% vs. 2.0%). Proliferative changes were noted in both epithelial and stromal cells.
Until such time as more data are available, caution should be exercised in adding testosterone to traditional hormone therapy regimens.
Hofling M, Hirschberg AL, Skoog L, et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause. 2007;14:183-190.
Burger HG. Should testosterone be added to estrogen-progestin therapy for breast protection? Menopause. 2007;14:159-162.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More